Fresenius Kabi’s mAbxience S.L. is set to play its part in a “historic milestone in the production of biopharmaceuticals in Turkey,” after announcing what was termed a “significant” technology transfer agreement with local player Abdi Ibrahim Pharmaceuticals, “specifically focusing on a crucial cancer drug.”
The transfer is set to enable the production of a ‘bio-product’ used in treating metastatic colorectal cancer, cervical cancer, and glioblastoma
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?